Matinas BioPharma (MTNB) News Today → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free MTNB Stock Alerts $0.16 0.00 (0.00%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | investorplace.comPenny Stock Sleepers: 7 Under-the-Radar Gems Ready to LaunchMay 16, 2024 | finance.yahoo.comNew In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024May 16, 2024 | globenewswire.comNew In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024May 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Matinas BioPharma on Strong Financials and Promising Oral Antifungal CandidateMay 10, 2024 | finance.yahoo.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comQ1 2024 Matinas BioPharma Holdings Inc Earnings CallMay 10, 2024 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateMay 9, 2024 | investorplace.comMTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q1 2024May 9, 2024 | globenewswire.comMatinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateMay 7, 2024 | finance.yahoo.comMatinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual MeetingMay 2, 2024 | globenewswire.comMatinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024April 30, 2024 | msn.comOral fungal infection treatment shows promise in preclinical trialsApril 30, 2024 | finance.yahoo.comIn Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and ChemotherapyApril 3, 2024 | msn.comMatinas Declines on Public OfferingApril 3, 2024 | globenewswire.comMatinas BioPharma Prices $10 Million Registered Direct OfferingApril 1, 2024 | finance.yahoo.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateMarch 28, 2024 | marketbeat.comMatinas BioPharma (NYSEAMERICAN:MTNB) Issues Earnings ResultsMatinas BioPharma (NYSEAMERICAN:MTNB - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.03) earnings per share (EPS) for the quarter.March 28, 2024 | finance.yahoo.comQ4 2023 Matinas BioPharma Holdings Inc Earnings CallMarch 27, 2024 | investorplace.comMTNB Stock Earnings: Matinas BioPharma Hldgs Reported Results for Q4 2023March 27, 2024 | globenewswire.comMatinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateMarch 25, 2024 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationMarch 25, 2024 | globenewswire.comMatinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationMarch 22, 2024 | finance.yahoo.comWhy Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?March 22, 2024 | finance.yahoo.comThree Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseMarch 22, 2024 | globenewswire.comThree Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseMarch 22, 2024 | globenewswire.comMatinas BioPharma Regains Compliance with NYSE American Continued Listing StandardsMarch 12, 2024 | marketbeat.comMatinas BioPharma (MTNB) to Release Quarterly Earnings on WednesdayMatinas BioPharma (NYSEAMERICAN:MTNB) will be releasing earnings on Wednesday, March 13, Yahoo Finance reports.March 3, 2024 | uk.finance.yahoo.comMatinas BioPharma Holdings, Inc. (MTNB)February 28, 2024 | wsj.comMatinas BioPharma Holdings Inc.February 26, 2024 | finance.yahoo.comMatinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical ResolutionFebruary 23, 2024 | benzinga.comMatinas BioPharma Hldgs Stock (AMEX:MTNB) Dividends: History, Yield and DatesFebruary 20, 2024 | finance.yahoo.comMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisFebruary 20, 2024 | globenewswire.comMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisFebruary 4, 2024 | seekingalpha.comAVBP ArriVent BioPharma, Inc.January 21, 2024 | morningstar.comMatinas BioPharma Holdings Inc MTNBJanuary 3, 2024 | finance.yahoo.comMatinas BioPharma to Present at Biotech Showcase 2024December 27, 2023 | finance.yahoo.comMatinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small OligonucleotidesDecember 21, 2023 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDADecember 21, 2023 | markets.businessinsider.comMatinas BioPharma Plans To Meet With FDA In Q1 To Finalize Phase 3 Protocol For MAT2203December 21, 2023 | finance.yahoo.comMatinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDADecember 20, 2023 | benzinga.comMatinas BioPharma Hldgs Stock (AMEX:MTNB), Guidance and ForecastNovember 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bolt Biotherapeutics (BOLT), Matinas BioPharma (MTNB) and Vor Biopharma (VOR)November 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Shattuck Labs (STTK) and Matinas BioPharma (MTNB)November 10, 2023 | finance.yahoo.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comQ3 2023 Matinas BioPharma Holdings Inc Earnings CallNovember 8, 2023 | finance.yahoo.comMatinas BioPharma Holdings Inc (MTNB) Reports Q3 2023 Financial Results and Business ProgressNovember 8, 2023 | finance.yahoo.comMatinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business UpdateNovember 7, 2023 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma ModelNovember 7, 2023 | finance.yahoo.comMatinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model Get Matinas BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon Musk’s Final Masterpiece: “X-9840” (Ad)The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. MTNB Media Mentions By Week MTNB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MTNB News Sentiment▼0.000.76▲Average Medical News Sentiment MTNB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MTNB Articles This Week▼01▲MTNB Articles Average Week Get Matinas BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ZOM News SGMT News IMAB News RPTX News VERU News CYDY News SCPH News RGLS News SYRS News RAPT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:MTNB) was last updated on 6/9/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredTime is Running Out - June 25th Deadline Approaching!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored